APM (Aptorum Group Ltd) Forward Price-to-Revenue Multiple

Aptorum Group Limited (APM) minimizes biotechnological risks by developing treatments for rare pathologies and infections. This chart of the company's expected P/S ratio visualizes the dynamics of market expectations, where 5.10 represents the current level of the metric. A strong patent portfolio and surgical robotics support the quality of capital, while an academic image in oncology ensures professional trust in the brand's research.

APM Aptorum Group Ltd: Market Cap to Future Revenue Ratio in the range 07/04/2022 - 12/21/2024

Metric breakdowns and analytics for aptorumgroup.com (APM)

- market price and analyst price targets:

Price Chart Aptorum Group|APM - Forecast Levels Chart

- business market valuation indicators:

Market Valuation APM|APM - Aggregate Business Value

- business book valuation details:

Net Assets per Single Share Aptorum Group|APM - Total Stockholders' Equity|Market Value to Book Value Ratio aptorumgroup.com|APM - Aggregate Asset Value

- debt obligations and liquidity statistics:

- business earnings and investment ratios data:

APM - Final Profit|Expected Profit Aptorum Group Limited|APM - Market Cap to Earnings|Projected Price to Earnings Aptorum Group|APM - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization APM|APM - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share for the last 12 months Aptorum Group|APM - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months aptorumgroup.com|APM - Earnings per share growth in current year|Earnings growth forecast for next year Aptorum Group Limited

- revenue and sales details:

APM - Company Gross Revenue|Company Projected Revenue Aptorum Group|APM - Market Cap to Revenue|Forward P/S Multiple APM

Analysis of all company metrics:Aptorum (APM)

It is essential for investors to determine an asset's fair value by comparing current market capitalization with projected annual revenue. By analyzing the forward P/S chart, one can assess the extent to which market expectations are overextended, which is critical for Aptorum Group Limited (APM) given its early-stage development and the high risk of failing to achieve commercial results amid a capital shortage.

Key competitors

Price-to-Projected Revenue Ratio Haleon HLN|KVUE (Kenvue Inc) - Future Price to Revenue|VRNA: Forward Price-to-Revenue Multiple|Jyong Bio - Price to Expected Revenue Ratio|Ligand Pharmaceuticals (LGND) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio amneal.com (AMRX)|Price-to-Projected Revenue Ratio Perrigo|ALVO: Forward Price to Sales|Forward Price-to-Revenue Multiple LQDA (Liquidia Technologies)|Forward P/S Multiple Galapagos Corp (GLPG)|Price-to-Projected Revenue Ratio ANI Pharmaceuticals ANIP|MNKD - Forward Price-to-Revenue Multiple|AMPH: Forward Price-to-Revenue Multiple|Forward Price to Sales PCRX (Pacira Pharmaceuticals)|SPRY: Forward P/S Multiple|Projected Price to Revenue Theravance Corp TBPH|Price-to-Projected Revenue Ratio Aquestive Therapeutics|SCPH: Forward Price to Sales|Price-to-Projected Revenue Ratio Tectonic Therapeutic, Inc. (TECX)|TNXP - Market Cap to Future Revenue Ratio|China SXT Pharmaceuticals, Inc. - Forward Price-to-Revenue Multiple|Forward P/S Multiple Eupraxia Pharmaceuticals, Inc. EPRX|BHST - Price-to-Projected Revenue Ratio|Future Price to Revenue EXOZ|ORMP (oramed.com) - Forward Price-to-Revenue Multiple|Entera Bio - Forward Price to Sales|Price-to-Projected Revenue Ratio MindWalk|Price-to-Projected Revenue Ratio ABVC|Forward P/S Multiple CPIX|Market Cap to Expected Sales Ratio quantumbiopharma.com|Price-to-Projected Revenue Ratio FibroGen FGEN|TELO - Forward Price-to-Revenue Multiple|Rani Therapeutics Inc - Forward P/S Multiple|Market Cap to Expected Sales Ratio Synergy CHC Corp SNYR|RLYB (rallybio.com) - Forward Price-to-Revenue Multiple|LEXX: Price to Expected Revenue Ratio|PULM (Pulmatrix) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Pheton PTHL|Forward P/S Multiple LYRA|Impact BioMedical, Inc. - Market Cap to Projected Revenue|Forward P/S Multiple TNFA (TNF Pharmaceuticals, Inc.)|Forward P/S Multiple cbdMD Inc. YCBD|PRFX - Price-to-Projected Revenue Ratio|Future Price to Revenue CYTO|Lipella (LIPO) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple OptiNose Corp|Price-to-Projected Revenue Ratio Pieris Pharmaceuticals|procapsgroup.com - Future Price to Revenue|Forward P/S Multiple PTPI|QLI (Qilian International Holding Group) - Forward Price to Sales|Forward P/S Multiple SLRN (ACELYRIN, Inc.)|Forward P/S Multiple TFF Pharmaceuticals, Inc TFFP